Mid-Atlantic BioTherapeutics, Inc.

Mid-Atlantic BioTherapeutics (MABT), founded in 2011 and headquartered in Doylestown, Pennsylvania, is a clinical-stage biotechnology company that utilizes advanced artificial intelligence and proprietary computational methods to drive drug discovery. The company focuses on developing novel immunotherapy solutions for challenging infectious diseases and central nervous system (CNS) disorders. Its lead proprietary technology platform, IMT504, is designed to harness the body's own immune response to treat severe infectious conditions, including rabies, for which it has received Orphan Drug Designation. Additionally, MABT is leveraging structural biology and AI-driven screening, through collaborations such as the one with Accelero BioStructures, to develop USP30 inhibitors aimed at addressing neurological conditions like Parkinson’s and Alzheimer’s disease.

These therapeutic efforts are critical to addressing significant unmet medical needs, particularly where existing treatments are limited or non-existent. By targeting intractable illnesses, MABT seeks to offer new treatment paradigms that can improve patient outcomes and alleviate the burdens of infectious and neurodegenerative diseases. The company’s leadership team comprises experienced scientists and pharmaceutical professionals with expertise in clinical development and commercialization. MABT actively engages in strategic licensing and research partnerships to advance its pipeline and expand its global market presence, supported by ongoing funding initiatives intended to accelerate clinical trials and discovery programs.